enGene Therapeutics Inc (ENGN) vs Nautilus Biotechnology, Inc. (NAUT)

enGene Therapeutics Inc and Nautilus Biotechnology, Inc. are both Biotechnology companies. enGene Therapeutics Inc and Nautilus Biotechnology, Inc. are of similar size ($128.7M and $126.1M). Across the 10 metrics below, Nautilus Biotechnology, Inc. leads on 6 and enGene Therapeutics Inc on 4.

Valuation

Metric ENGN NAUT Biotechnology median
P/E n/m n/m 7.88
P/S n/m n/m 11.47
P/B 0.59 0.94 2.52
Price to free cash flow n/m n/m 21.16
EV/EBITDA 0.76 n/m 0.74
EV/Sales n/m n/m 10.73
Earnings yield (105.41%) (46.39%) (28.84%)
Free cash flow yield (76.09%) (42.05%) (23.03%)

Profitability

Metric ENGN NAUT Biotechnology median
Gross margin — 0.00% 65.16%
Operating margin 0.00% 0.00% 0.00%
Net margin 0.00% 0.00% 0.00%
Free cash flow margin 0.00% 0.00% 0.00%
Return on equity (60.50%) (36.21%) (57.72%)
Return on assets (48.84%) (30.00%) (49.22%)
Return on invested capital 0.00% (83.32%) 0.00%

Growth

Metric ENGN NAUT Biotechnology median
Revenue growth (TTM) — — 5.64%
EPS growth (last fiscal year) (56.85%) 16.07% —
Revenue growth, 5-year CAGR — — 8.40%
Net income growth, 5-year CAGR 0.00% 0.00% 0.00%

Health

Metric ENGN NAUT Biotechnology median
Debt to equity 0.11 0.00 0.00
Current ratio 10.21 10.14 4.73
Net debt to EBITDA 1.42 1.67 0.96

Dividend

Metric ENGN NAUT Biotechnology median
Dividend yield — — 2.10%
Payout ratio 0.00 0.00 0.00

Size

Metric ENGN NAUT Biotechnology median
Market cap 128.67m 126.05m 162.10m

Compare with another peer

Any metric, up to five companies and an Excel export Powerpack